Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET-Mutated NSCLC with Major Response to Crizotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2015

Mendenhall Melody A, Goldman Jonathan W

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Crizotinib
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Retreatment

Source

Identifiers

PMID: 25898965
DOI: 10.1097/JTO.0000000000000491

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET-Mutated NSCLC with Major Response to Crizotinib.PMID 25898965Read ↗

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.Semantic proximity Read ↗

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.Semantic proximity Read ↗

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.Semantic proximity Read ↗

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.Semantic proximity Read ↗

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.Semantic proximity Read ↗

MET Mutation Associated with Responsiveness to Crizotinib.Semantic proximity Read ↗

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.Semantic proximity Read ↗

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.Semantic proximity Read ↗

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.Semantic proximity Read ↗

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.Semantic proximity Read ↗

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.